Related Experiment Videos
Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy
Kristl Vonck1, Paul Boon, Erik Achten
1Reference Center for Refractory Epilepsy, Department of Neurology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. kristl.vonck@mri2.rug.ac.be
Annals of Neurology
|October 29, 2002
Summary
Long-term deep brain stimulation (DBS) effectively reduced seizures in epilepsy patients. This study shows DBS is a feasible and safe treatment for refractory temporal lobe epilepsy.
Area of Science:
- Neurology
- Neurosurgery
Background:
- Refractory temporal lobe epilepsy (TLE) poses significant treatment challenges.
- Short-term deep brain stimulation (DBS) has shown promise for TLE management.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of DBS in medial temporal lobe structures for TLE.
- To assess the utility of chronic DBS electrodes for ictal onset zone localization prior to stimulation.
Main Methods:
- Implantation of DBS electrodes in the amygdalohippocampal region of three patients with complex partial seizures (CPSs).
- Recording electroencephalograms (EEGs) via DBS electrodes for ictal onset zone identification.
- Performing unilateral amygdalohippocampal stimulation and comparing CPS frequency before and after treatment.
- Monitoring for side effects throughout the study.
Main Results:
- High-quality EEG recordings accurately localized unilateral seizure onset in medial temporal lobe structures.
- All patients experienced a >50% reduction in seizure frequency after a mean 5-month follow-up.
- Two patients were able to reduce their antiepileptic drug dosage.
- No adverse side effects were reported by any patient.
Conclusions:
- Chronic DBS using implanted electrodes is a feasible method for ictal onset zone localization and treatment in TLE.
- Long-term DBS of medial temporal lobe structures demonstrates efficacy and safety in refractory TLE.
- Further research with larger cohorts is warranted to confirm DBS as an alternative TLE treatment.